Does Wavelength Matter When Photocoagulating Eyes With Macular Degeneration or Diabetic Retinopathy?-Reply

Research output: Contribution to journalLetterpeer-review

Abstract

In reply The preliminary work by Brancato and colleagues on the clinical efficacy of diode laser panretinal photocoagulation in eyes with proliferative diabetic retinopathy is duly noted. Unfortunately, the sample size required to evaluate a treatment difference between panretinal photocoagulation performed with argon green vs diode laser is far greater than that which appears in published reports. Thus, it is not yet possible to conclude that the two laser wavelengths provide comparable treatment benefits with equivalent risks. In fact, the work of Brancato and colleagues suggests that diode laser panretinal photocoagulation produces greater patient discomfort, requires more laser sessions to place the treatment, precipitates choroidal detachments, and produces more confluent chorioretinal atrophy than is customarily encountered with argon panretinal photocoagulation. Certainly, a larger-scale and longer-term study is needed to reliably evaluate these issues.

Original languageEnglish (US)
Number of pages1
JournalArchives of ophthalmology
Volume112
Issue number2
DOIs
StatePublished - Feb 1994
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Does Wavelength Matter When Photocoagulating Eyes With Macular Degeneration or Diabetic Retinopathy?-Reply'. Together they form a unique fingerprint.

Cite this